Loading clinical trials...
Loading clinical trials...
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Kariya Pharmaceuticals
NCT06513026 · Lactose Intolerance, Lactose Intolerant, and more
NCT07286747 · Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
NCT07440147 · Obesity & Overweight, Circadian Rhythm Disorders, and more
NCT07422272 · Pain Threshold, Pain Tolerance, and more
NCT06603883 · Gastrointestinal Dysfunction-induced Enteral Nutrition Intolerance
MAC
Manchester
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions